Compare DRS & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRS | ARWR |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.4B |
| IPO Year | N/A | 1993 |
| Metric | DRS | ARWR |
|---|---|---|
| Price | $41.34 | $69.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $46.83 | ★ $75.20 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 02-24-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $3,569,000,000.00 | $829,448,000.00 |
| Revenue This Year | $11.94 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | $41.91 | ★ N/A |
| Revenue Growth | 12.27 | ★ 23258.15 |
| 52 Week Low | $28.17 | $9.57 |
| 52 Week High | $49.31 | $76.76 |
| Indicator | DRS | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 59.54 |
| Support Level | $40.10 | $61.65 |
| Resistance Level | $43.25 | $68.24 |
| Average True Range (ATR) | 1.37 | 3.91 |
| MACD | 0.33 | -0.44 |
| Stochastic Oscillator | 79.14 | 53.90 |
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.